Belantamab plus other medicines for relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 study tests whether belantamab mafodotin combined with carfilzomib, pomalidomide, and dexamethasone can better treat multiple myeloma that has come back. It may help people who have already tried other myeloma treatments but whose cancer has progressed again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You should be expected to live more than 3 months.
- You can’t be severely limited in daily activities (ECOG 0–2).
- Your recent body organ tests (labs) must be within study-required limits.
- You must be willing to follow study safety rules, including special REMS program requirements for belantamab and pomalidomide.
- You must have relapsed multiple myeloma that has progressed after at least 2 prior treatment “lines,” and you must have measurable disease on specific lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether adding belantamab mafodotin to a combination treatment (daratumumab, pomalidomide, and dexamethasone) is safe and can shrink multiple myeloma in people whose disease is back or not responding. It is for people who have only had one prior treatment and cannot respond to lenalidomide.
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
This early-phase study tests how safe and effective belantamab mafodotin is when combined with lenalidomide and dexamethasone, plus a medicine called nirogacestat, in people with newly diagnosed multiple myeloma who cannot have stem cell transplant. It may help shrink the cancer and improve outcomes, while doctors track side effects.
This study looks at how well a treatment combining belantamab with other drugs works for patients whose multiple myeloma has come back. It may be an option if you have already received this drug combination on a compassionate use basis.
This Phase 1/2 trial tests whether combining belantamab mafodotin with venetoclax can treat multiple myeloma that has come back or did not respond (relapsed/refractory). It focuses on a specific myeloma subtype with a t(11;14) genetic marker, aiming to reduce the cancer in people who have already had several treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.